Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Xencor stock | 40.58

Own Xencor stock in just a few minutes.


Fact checked

Xencor, Inc is a biotechnology business based in the US. Xencor shares (XNCR) are listed on the NASDAQ and all prices are listed in US Dollars. Xencor employs 166 staff and has a trailing 12-month revenue of around USD$84.4 million.

How to buy shares in Xencor

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Xencor. Find the stock by name or ticker symbol: XNCR. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Xencor reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$40.58, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Xencor, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Xencor. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Xencor share price

Use our graph to track the performance of XNCR stocks over time.

Xencor shares at a glance

Information last updated 2020-11-30.
Latest market close USD$40.58
52-week range USD$19.35 - USD$43.9
50-day moving average USD$40.2041
200-day moving average USD$35.495
Wall St. target price USD$49.64
PE ratio 67.3913
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.607

Buy Xencor shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Xencor stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Xencor price performance over time

Historical closes compared with the close of $40.58 from 2020-11-16

1 week (2020-11-20) N/A
1 month (2020-10-30) 5.73%
3 months (2020-08-28) N/A
6 months (2020-05-28) N/A
1 year (2019-11-27) N/A
2 years (2018-11-27) N/A
3 years (2017-11-27) N/A
5 years (2015-11-27) N/A

Is Xencor under- or over-valued?

Valuing Xencor stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Xencor's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Xencor's P/E ratio

Xencor's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 67x. In other words, Xencor shares trade at around 67x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Xencor's EBITDA

Xencor's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$27.5 million.

The EBITDA is a measure of a Xencor's overall financial performance and is widely used to measure a its profitability.

Xencor financials

Revenue TTM USD$84.4 million
Gross profit TTM USD$38.1 million
Return on assets TTM -8.77%
Return on equity TTM -14.01%
Profit margin -97.86%
Book value $9.908
Market capitalisation USD$2.4 billion

TTM: trailing 12 months

Shorting Xencor shares

There are currently 3.9 million Xencor shares held short by investors – that's known as Xencor's "short interest". This figure is 1.3% up from 3.8 million last month.

There are a few different ways that this level of interest in shorting Xencor shares can be evaluated.

Xencor's "short interest ratio" (SIR)

Xencor's "short interest ratio" (SIR) is the quantity of Xencor shares currently shorted divided by the average quantity of Xencor shares traded daily (recently around 233067.71273386). Xencor's SIR currently stands at 16.57. In other words for every 100,000 Xencor shares traded daily on the market, roughly 16570 shares are currently held short.

However Xencor's short interest can also be evaluated against the total number of Xencor shares, or, against the total number of tradable Xencor shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Xencor's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Xencor shares in existence, roughly 70 shares are currently held short) or 0.1421% of the tradable shares (for every 100,000 tradable Xencor shares, roughly 142 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Xencor.

Find out more about how you can short Xencor stock.

Xencor share dividends

We're not expecting Xencor to pay a dividend over the next 12 months.

Xencor share price volatility

Over the last 12 months, Xencor's shares have ranged in value from as little as $19.35 up to $43.9. A popular way to gauge a stock's volatility is its "beta".

XNCR.US volatility(beta: 0.97)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Xencor's is 0.9684. This would suggest that Xencor's shares are less volatile than average (for this exchange).

Xencor overview

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases. It develops its antibody product candidates to treat cancer and autoimmune diseases. The company's product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; AIMab7195, which is in development and commercialization stage. Its product candidates also comprise XmAb14045, a bispecific antibody which is in Phase I clinical trial for the treatment of acute myeloid leukemia; plamotamab (XmAb13676) that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers Tafasitamab, an antibody drug candidate for the treatment of patients with relapsed/refractory diffuse; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG509, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, and XmAb23104 which are in preclinical Phase. Additionally, it offers XmAb24306, initial cytokine candidate which is in Phase I clinical trial. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; Amgen Inc.; and Catalent Pharma Solutions LLC., as well as a clinical collaboration with MorphoSys AG and Incyte Corporation to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site